PXD101
Information
- Drug Name
- PXD101
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| PXD101 is a HDAC inhibitor | PRAME | PRAME UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00131261 | Completed | Phase 2 | Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma | January 2005 | June 2007 |
| NCT00878722 | Completed | Phase 1/Phase 2 | Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy | August 2007 | April 2012 |
| NCT00878800 | Completed | Phase 1/Phase 2 | A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas | December 2006 | October 2012 |
| NCT00431340 | Terminated | Phase 2 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma | March 2007 | June 2007 |